Tatiana Prowell

Last updated

Awards and honours

Prowell was the recipient of an American Society of Clinical Oncology Young Investigator Award and two Pearl M. Stetler awards for women in medicine. [37] In 2019, she received the John and Samuel Bard Award in Science or Medicine for her contributions to the field of oncology. [38] Prowell was also recognized as one of the 100 Influential Women in Oncology by OncoDaily. [39]

Personal life

In 2004 she married Todd Gleeson, an HIV specialist. [40]

Related Research Articles

<span class="mw-page-title-main">Small-cell carcinoma</span> Type of malignant cancer

Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma is more aggressive, with a shorter doubling time, higher growth fraction, and earlier development of metastases.

<span class="mw-page-title-main">Pemetrexed</span> Chemical compound

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

<span class="mw-page-title-main">Pertuzumab</span> Pharmaceutical drug

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

<span class="mw-page-title-main">Metastatic breast cancer</span> Type of cancer

Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer where the breast cancer cells have spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer; there is no stage after IV.

<span class="mw-page-title-main">Olaparib</span> Chemical compound (cancer therapy drug)

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

<span class="mw-page-title-main">Lenvatinib</span> Chemical compound

Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

<span class="mw-page-title-main">Veliparib</span> Chemical compound

Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.

<span class="mw-page-title-main">Trastuzumab emtansine</span> Pharmaceutical drug

Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1.

<span class="mw-page-title-main">Temozolomide</span> Cancer medication

Temozolomide, sold under the brand name Temodar among others, is an anticancer medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.

<span class="mw-page-title-main">Nivolumab</span> Anticancer medication

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

<span class="mw-page-title-main">Atezolizumab</span> Monoclonal anti-PD-L1 antibody

Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

<span class="mw-page-title-main">Abemaciclib</span> Anti-breast cancer medication

Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.

<span class="mw-page-title-main">Tucatinib</span> Chemical compound

Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.

Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults. It is a combination of trastuzumab and hyaluronidase.

Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.

References

  1. "Clinical Trials for People with Metastatic Breast Cancer with Dr. Tatiana Prowell". realpink.komen.org. January 6, 2020. Retrieved June 2, 2020.
  2. Piana, Ronald (September 10, 2019). "Insightful Advice From a College Advisor Leads to an Unexpected Career in Oncology". ascopost.com. Retrieved June 2, 2020.
  3. 1 2 "How I Became an Academic Oncologist and FDA Medical Officer and Scientific Liaison". connection.asco.org. February 26, 2018. Retrieved June 2, 2020.
  4. Pendered, Daniel (November 1, 1988). "From 'Yuppie' Parkview High School, Students Demand Amnesty For Others". The Atlanta Constitution. Retrieved June 3, 2020.
  5. "Students Elected to Phi Beta Kappa April 1999". pages.jh.edu. April 1999. Retrieved June 2, 2020.
  6. Pickert, Kate (October 1, 2019). Radical: The Science, Culture, and History of Breast Cancer in America. Little, Brown and Company. p. 230. ISBN   9780316470339 . Retrieved June 3, 2020.
  7. Steenhuysen, Julie (June 4, 2012). "U.S. regulators to allow women to test breast cancer drugs earlier". The Ottawa Citizen. Retrieved June 3, 2020 via Newspapers.com.
  8. "Tatiana Prowell, MD". aaadv.org. Retrieved June 3, 2020.
  9. https://www.fda.gov/media/83507/download
  10. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-role-pathological-complete-response-endpoint-neoadjuvant-breast-cancer-studies_en.pdf
  11. Prowell, Tatiana M.; Beaver, Julia A.; Pazdur, Richard (February 14, 2019). "Residual Disease after Neoadjuvant Therapy — Developing Drugs for High-Risk Early Breast Cancer". New England Journal of Medicine. 380 (7): 612–615. doi:10.1056/NEJMp1900079. PMID   30763188. S2CID   73437766.
  12. Prowell, Tatiana M.; Pazdur, Richard (June 28, 2012). "Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer". New England Journal of Medicine . 366 (26): 2438–2441. doi:10.1056/NEJMp1205737. PMID   22646508.
  13. "Men Develop Breast Cancer, Too".
  14. "Men with Breast Cancer Need More Treatment Options and Access to Genetic Counseling". FDA. 15 June 2021.
  15. "Cancer Immunology Working Group" (PDF). cancer.gov. October 17, 2016. p. 67. Retrieved June 3, 2020.
  16. Kim, Edward S.; Bruinooge, Suanna S.; Roberts, Samantha; Ison, Gwynn; Lin, Nancy U.; Gore, Lia; Uldrick, Thomas S.; Lichtman, Stuart M.; Roach, Nancy; Beaver, Julia A.; Sridhara, Rajeshwari; Hesketh, Paul J.; Denicoff, Andrea M.; Garrett-Mayer, Elizabeth; Rubin, Eric; Multani, Pratik; Prowell, Tatiana M.; Schenkel, Caroline; Kozak, Marina; Allen, Jeff; Sigal, Ellen; Schilsky, Richard L. (20 November 2017). "Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement". Journal of Clinical Oncology. 35 (33): 3737–3744. doi:10.1200/JCO.2017.73.7916. PMC   5692724 . PMID   28968170.
  17. "Pink Sheet - Cancer Trials: Broader Eligibility Criteria Could Mean Novel Labeling Claims - Friends of Cancer Research". Friends of Cancer Research.
  18. Lin, Nancy U.; Prowell, Tatiana; Tan, Antoinette R.; Kozak, Marina; Rosen, Oliver; Amiri-Kordestani, Laleh; White, Julia; Sul, Joohee; Perkins, Louise; Beal, Katherine; Gaynor, Richard; Kim, Edward S. (20 November 2017). "Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group". Journal of Clinical Oncology. 35 (33): 3760–3773. doi:10.1200/JCO.2017.74.0761. PMID   28968165.
  19. https://ctep.cancer.gov/protocoldevelopment/docs/CTEP_Memorandum_Broaden_Eligibility_Criteria_Initiative.pdf
  20. "Trastuzumab Deruxtecan Induces Responses in Patients with HER2+ Breast Cancer and Brain Metastases". 28 July 2022.
  21. Lin, Nancy U.; Murthy, Rashmi K.; Abramson, Vandana; Anders, Carey; Bachelot, Thomas; Bedard, Philippe L.; Borges, Virginia; Cameron, David; Carey, Lisa A.; Chien, A. Jo; Curigliano, Giuseppe; Digiovanna, Michael P.; Gelmon, Karen; Hortobagyi, Gabriel; Hurvitz, Sara A.; Krop, Ian; Loi, Sherene; Loibl, Sibylle; Mueller, Volkmar; Oliveira, Mafalda; Paplomata, Elisavet; Pegram, Mark; Slamon, Dennis; Zelnak, Amelia; Ramos, Jorge; Feng, Wentao; Winer, Eric (2023). "Tucatinib vs Placebo, Both in Combination with Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients with Brain Metastases". JAMA Oncology. 9 (2): 197–205. doi:10.1001/jamaoncol.2022.5610. PMC   9716438 . PMID   36454580.
  22. "Melanoma Brain Metastases: 'Absolutely Treatable in 2021'". 5 July 2021.
  23. Abramowitz, Ben (July 19, 2019). "These Are the Words Doctors Should Stop Saying". syneoshealthcommunications.com. Syneos Health Communications. Retrieved June 3, 2020.
  24. Zitella, L. J.; Prowell, T. M. (2021). "Words Matter: Use of Respectful Language in Oncology". Journal of the Advanced Practitioner in Oncology. 12 (3): 241–243. doi:10.6004/jadpro.2021.12.3.3. PMC   8087234 . PMID   34084566.
  25. Dizon, Don S.; Prowell, Tatiana M. (June 17, 2019). "'An Emotional Slap in the Face': The Language of Cancer". medscape.com. Medscape . Retrieved June 3, 2020.
  26. Cavallo, Jo (April 10, 2020). "What's in a Name?". ascopost.com. Retrieved June 3, 2020.
  27. "Journal of Clinical Oncology (JCO) Podcast: What's in a Name? An Introductory Guide".
  28. ""Call me Doctor" How women in oncology are fighting for cultural change". 13 December 2019.
  29. https://twitter.com/tmprowell/status/1533035835364450307?s=20
  30. "Program Guide – ASCO Meeting Program Guide".
  31. "10 Women in Medicine You Need to Follow on Social Media". 25 March 2022.
  32. Zhang, Sarah (March 28, 2020). "America Needs Plasma From COVID-19 Survivors Now". The Atlantic . Retrieved June 3, 2020.
  33. @sarahzhang (April 10, 2020). "Wow, Mt. Sinai says 20,000 people have reached out to donate plasma. 125 people have donated/are scheduled to donate. 37 patients have received plasma so far" (Tweet) via Twitter.
  34. "The 24th Annual Webby Awards Celebrates & Honors the Individuals and Organizations Using the Internet in Response to COVID-19". webbyawards.com. 2020. Retrieved June 2, 2020.
  35. "Explore the Space".
  36. "Healthcare Workers vs Hunger". Healthcare Workers vs Hunger. Retrieved 2023-12-31.
  37. "Bard College Awards Recipients". annandaleonline.org. Retrieved June 2, 2020.
  38. "Bard College Holds One Hundred Fifty-Ninth Commencement on Saturday, May 25, 2019". bard.edu. May 25, 2019. Retrieved June 3, 2020.
  39. "100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023". OncoDaily. 16 September 2023.
  40. "Bardian 2004 Summer". May 31, 2004. p. 62. Retrieved June 2, 2020.
Tatiana Prowell
Tatiana Prowell Headshot.jpg
Born
Atlanta, Georgia, USA
Spouse
Todd Gleeson
(m. 2002)
Children3
Academic background
EducationB.A., literature and language, 1994, Bard College
M.D., 1999, Johns Hopkins University School of Medicine